STL Index for: Ayaa Alkhaleefa

Dupilumab for the Treatment of Prurigo Nodularis

Dupilumab: A groundbreaking FDA and Health Canada-approved treatment for Prurigo Nodularis (PN). This innovative therapy targets IL-4 and IL-13 signalling, effectively reducing inflammation, pruritus, and lesions. Its approval marks a paradigm shift in PN management, offering new hope for patients.

POPULAR

Advertisement